Advisory Board and Editors Cell Biology
Korakot Nganvongpanit
Korakot Nganvongpanit, B.Sc., D.V.M., Ph.D., D.T.B.V.S. is Professor of Veterinary Medicine at the Chiang Mai University, Faculty of Veterinary Medicine, Thailand. He is the head of Animal Bone and Joint Research Laboratory, Faculty of Veterinary Medicine, Chiang Mai University over 15 years, and head of Excellence Center in Veterinary Bioscience, Chiang Mai University.
His research experience focusing on osteology and related areas includes molecular biology/genetic, chondrocyte culture, small animals orthopedic, and rehabilitation. Past projects involved multi-disciplinary research in the areas of animal osteology including; osteoarthritis (in vivo and in vitro), molecular biology/genetic, forensic anthropology, and population genetics.
Corey Nislow
Corey Nislow's laboratory develops and uses cutting edge tools to address this central question: how can we understand the biological commonalities in all of the life sciences; from embryonic development, to the spread of infectious diseases to better ways to treat cancer. Each of these disciplines can be explained in the context of competition, interaction and evolution. His lab studies the interface between genes and the environment using parallel genome-wide screens, high throughput cell-based assays and next generation sequencing. Most recently, he and his scientific partner, Dr. Guri Giaever, are exploring how laboratory experiments can co-opt evolutionary processes to understand drug action. He enjoys teaching all aspects of biotechnology, genomics and drug discovery. He got his PhD from the University of Colorado, worked at several Biotechnology companies and was at Stanford and University of Toronto before joining UBC in 2013. He has published 161 papers and run 19 marathons.
Lorraine O'Driscoll
Lorraine O'Driscoll (BSc(Hons, Pharm), MSc(Res, Clin Pharm), MA(Ed), PhD(Biotech), FTCD) Lorraine holds a BSc(Hons),pharmacology; MSc(Res), clinical pharmacology; MA, education; PhD, biotechnology. In 2012, she was elected to Fellowship in TCD. Following her PhD, Lorraine undertook biotechnology/biomedical research for US and EU industry (including Berlex; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academia. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader and Lecturer in School of Biotechnology, DCU.
Her research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer.
She has been a P.I. on 5 cancer clinical trials with ICORG. She is TCD's Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported Breast-PREDICT; and P.I. and Chair, H2020-supported European Network Cooperation in Science and Technology focussed on Exosomes & Microvesicles in Health & Disease which brings together researchers from around the world, in academia and industry.
Olorunseun O Ogunwobi
Dr. Ogunwobi obtained a medical degree from the University of Ibadan, Nigeria, a master's degree in biomedicine from the University of Hull, United Kingdom, a master's degree in clinical and translational science from the University of Florida, Gainesville, and a PhD in molecular biology from the University of East Anglia, Norwich, United Kingdom. He was the Founding Director of the Hunter College Center for Cancer Health Disparities Research. He is now the Barnett Rosenberg Professor of Biochemistry and Molecular Biology and Chairperson in the Department of Biochemistry and Molecular Biology at Michigan State University. In addition, he will serve as Co-Director of the forthcoming Center for Cancer Health Equity Research (CCHER) at Michigan State University. He is a translational cancer biologist whose work focuses on molecular mechanisms of progression of solid organ cancers with racial disparities, and on approaches to leverage non-coding RNA biology for potential clinical applications in cancer. His work has been funded by the National Institutes of Health, New York State, Carnegie Corporation of New York, and the National Science Foundation, among others. Dr. Ogunwobi was a Founding Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by U54 grants CA221704 and CA221705 from the National Cancer Institute. An author of 74 peer-reviewed journal articles and 3 book chapters, Dr. Ogunwobi has been issued 5 US patents for biotechnology inventions with potential clinical applications in cancer. He is the recipient of the 2022 Hunter College Presidential Award for Excellence in Scholarship or Creative Activity, and selected as a Jefferson Science Fellow by the National Academies of Sciences, Engineering, and Medicine, and as a Fellow of the Academy of Medicine Specialties of Nigeria. He is Co-Founder of UTR Therapeutics, Inc (winner of the 2023 XSeed Award from Deerfield), and NucleoBio, Inc.
Sonia MR Oliveira
Doctor Sonia Oliveira holds a Licenciatura in Biology (pre-Bologna) and a Master in Cellular and Molecular Biology from the University of Aveiro, where she also specialized in medicinal plants, toxicology, murine models, and spermatogenesis. In 2011 she moved to Australia to work in Reproductive Biological Sciences. She later explored the nerve-cancer connection in Cancer, namely in female cancers, and completed her Ph.D. in Human Physiology ( with a significant component in Medical Biochemistry and Neurophysiology) from the University of Newcastle (Australia) in 2018. She then worked with biomimetic systems and nanotechnology in diabetes and stem cells. She explored multiple methods for primary and secondary cell culture, always with a keen interest in histopathology, cell biology, and rare disorders. Participated in >40 event(s). (Co-)Supervised MSc dissertation(s) and final projects for course completion of LSc/BSc. And works mostly in the area(s) of Natural sciences with emphasis on Molecular and Cellular Biology, and Medical and Health Sciences with emphasis on Neurosciences, Cancer, Reproduction, Toxicology, Biotechnology, and Stem cells. Also has collaborations in Microbiology, Biomaterials, and Communication and Information technologies.
Michael F Olson
Professor and Tier 1 Canada Research Chair in the Department of Chemistry and Biology of Ryerson University in Toronto Canada. Professor Olson's lab has focused on characterizing how Rho GTPase signalling pathways contribute to cancer, with the ultimate goal of identifying critical elements that could be targeted with small molecule inhibitors. Editor in Chief of the journal Small GTPases, and on the editorial boards of Molecular and Cellular Biology, Journal of Molecular Medicine, PLoS One, Scientific Reports. Science Proceedings, F1000 Research and PeerJ. Elected as a Fellow of the Royal Society of Biology.
Isabel M Palacios
University at Madrid, Spain; PhD at EMBL Germany; Postdoc at the Gurdon Institute, Cambridge, UK; Group Leader as a Royal Society University Research Fellow and currently as a University Senior Research Fellow, Cambridge, UK. Also a Fellow of St John's College, Cambridge, UK
Sean P. Palecek
Professor of Chemical & Biological Engineering at the University of Wisconsin - Madison.
Amaresh Chandra Panda
Dr. Panda obtained his Ph.D. in Biotechnology from National Centre for Cell Science, University of Pune, India. He worked as a Postdoctoral Fellow for five years at the National Institute on Aging, National Institutes of Health (NIH), Baltimore, USA. He also worked as an Assistant Scientist at the University of Miami, Miami, USA, and as a Postdoctoral Fellow at the University of Colorado, Denver, USA. His studies have uncovered new mechanistic details of the post-transcriptional regulation by RNA-binding proteins, microRNAs, and circular RNAs in physiological processes, including insulin production, myogenesis, and cellular senescence. In 2019, he was awarded the prestigious Intermediate Fellowship by Wellcome Trust/DBT India Alliance. Currently, he is working as a Scientist-D at ILS Bhubaneswar under the Department of Biotechnology, Government of India. His research group at ILS is working to understand the role of poorly characterized circRNAs in muscle regeneration and insulin biosynthesis.
Anurag N Paranjape
Passionate about understanding the mechanisms governing cancer metastasis with a hope of finding new targetable pathways. Have worked on breast cancer stem cells, EMT, prostate cancer stem cells, breast cancer brain metastasis, and blood-brain barriers.
Eun-Jung Park
Eun-Jung Park, Assistant Professor of Toxicology and Pharamcology, Director of Flow Cytometry Core in Pharmaceutical Sciences, Long Island University - Brooklyn Campus
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University
Anup Singh Pathania
Dr. Anup Pathania is an Assistant Professor at the University of Nebraska Medical Center (UNMC).
His research interests include non-coding RNAs in cancer, pharmacology, and immunology. He is currently investigating the underlying mechanisms in the stabilization of PD-L1 by exosomal non-coding RNAs in neuroblastoma cells within the tumor microenvironment.